Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 14Unknown 5Recruiting 5Active not recruiting 5Not yet recruiting 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 902Lung Neoplasms 489Small Cell Lung Carcinoma 140Neoplasms 111Melanoma 107Neoplasm Metastasis 105Breast Neoplasms 99Colorectal Neoplasms 94Ovarian Neoplasms 76Carcinoma, Renal Cell 64Pancreatic Neoplasms 62Squamous Cell Carcinoma of Head and Neck 58Mesothelioma 53Stomach Neoplasms 51Head and Neck Neoplasms 47Adenocarcinoma of Lung 46Triple Negative Breast Neoplasms 45Esophageal Neoplasms 40Colonic Neoplasms 40Brain Neoplasms 40Sarcoma 38Mesothelioma, Malignant 38Prostatic Neoplasms 37Urinary Bladder Neoplasms 36Recurrence 30Carcinoma, Transitional Cell 28Uterine Cervical Neoplasms 25Endometrial Neoplasms 25Carcinoma, Hepatocellular 21Carcinoma, Squamous Cell 19

Interventions

lenvatinib 1Pemetrexed 1Docetaxel 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Advanced Non-small Cell Lung Cancer × Thoracic × Clear all
NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 2/3 Terminated
16 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT02200354 2019-08-14

The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

Kobe City General Hospital

Phase 2 Terminated
20 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡